Endoscopic ultrasound (EUS) and the management of pancreatic cancer

Muhammad Nadeem Yousaf, Fizah S Chaudhary, Amrat Ehsan, Alejandro L Suarez, Thiruvengadam Muniraj, Priya Jamidar, Harry R Aslanian, James J Farrell

ABSTRACT
Pancreatic cancer is one of the leading causes of cancer-related mortality in western countries. Early diagnosis of pancreatic cancers plays a key role in the management by identification of patients who are surgical candidates. The advancement in the radiological imaging and interventional endoscopy (including endoscopic ultrasound (EUS), endoscopic retrograde cholangiopancreatography and endoscopic enteral stenting techniques) has a significant impact in the diagnostic evaluation, staging and treatment of pancreatic cancer. The multidisciplinary involvement of radiology, gastroenterology, medical oncology and surgical oncology is central to the management of patients with pancreatic cancers. This review aims to highlight the diagnostic and therapeutic role of EUS in the management of patients with pancreatic malignancy, especially pancreatic ductal adenocarcinoma.

INTRODUCTION
Pancreatic cancer is the fourth leading causes of cancer-related death in the USA with an estimated of 55,600 (30,400 men and 27,200 women) new cases, and 47,050 (24,640 men and 22,410 women) deaths in 2020. The highest incidence rate is reported in North America and Europe while lowest in Africa and South Central. The common risk factors for pancreatic cancer are smoking, positive family history, genetics, alcohol consumption, obesity, diabetes, diet and physical inactivity. Overall 5-year survival rate is 8% (ranging from 2% to 9%). The poor outcome of the disease is due to metastatic or local advancement of disease at time of diagnosis in the majority of patients. The introduction of newer medical therapies (including neoadjuvant chemotherapy approaches) and improvement of surgical techniques for resection of pancreatic cancer has had modest impact on the outcome of disease in last decade. Because of the rising disease burden, there is an increasing emphasis on early identification of pancreatic cancers and premalignant pancreatic lesions in high-risk individuals. Advancement in technology to improve both non-invasive imaging (CT scan, MRI, nuclear imaging) and minimally invasive imaging (endoscopic ultrasound (EUS), endoscopic retrograde cholangiopancreatography (ERCP)) plays an important role in early detection of pancreatic cancers. Specifically, EUS has a central role in diagnosis, staging, palliative therapy and increasingly the therapy of pancreatic cancers.

ENDOSCOPIC ULTRASOUND
EUS is an endoscopic imaging modality which provides a detailed and high-resolution spatial imaging of the pancreas compared with CT or MRI through the addition of an ultrasound transducer on the tip of the flexible endoscope. Linear EUS performs imaging in the same plane as shaft of the endoscope, whereas with radial EUS circumferential viewing can be obtained in the plane perpendicular to the shaft of the endoscope. EUS provides the added advantage of high resolution imaging for the identification and evaluation of small pancreatic masses and cysts by taking magnified imaging due to close proximity of EUS transducer to the pancreas by positioning the transducer in the gastro-oesophageal junction (GOJ), bulb and second portion of the duodenum, and by eliminating the effect of intestinal gas and fat.

EUS-GUIDED DIAGNOSTIC INTERVENTIONS
EUS evaluation of solid pancreatic mass lesions
Because of the rising incidence of pancreatic cancer and limited treatment, there is increased emphasis on early detection of pancreatic cancer. Pancreatic intraepithelial neoplasm (PanIN) is a pre-invasive form of pancreatic cancer, has potential for malignant transformation to pancreatic adenocarcinoma. It has been suggested that early PanIN 1 lesions can progress to adenocarcinoma in 1.3% in women and 1.5% in men.
over a lifetime period, and that more advanced PanIN 3 lesions can progress to adenocarcinoma over an estimated period of 12.3 years in women and 11.3 years in men. However, due to lack of optimum screening tests including the ability to visualize these PanIN lesions, early detection of pancreatic lesions is challenging. Pancreatic cancer screening of the general population is not recommended because of low disease prevalence. The screening of high-risk populations including those with familial pancreatic cancer and those with known germline genetic mutations for the development of pancreatic cancers (eg, BRCA 2, BRCA1, p16) are the potential targets. Non-invasive imaging (such as MRI and CT scan) and minimally invasive imaging with EUS are the main screening tools for these high-risk population. Early data suggest a survival benefit to diagnosing early pancreatic cancer within these high surveillance programs.

EUS is more sensitive, specific and accurate in the detection of pancreatic lesions than high-quality cross-sectional imaging. Numerous studies (n=23) have shown high sensitivity (92%–100%), specificity (89%–100%) and accuracy (86%–99%) of EUS in the detection of pancreatic malignancies which is higher than that of CT scan, particularly with small diameter pancreatic lesions. The additional advantages of EUS over cross-sectional images are especially for small pancreatic masses (0.5–2 cm) and the ability to perform EUS-guided fine needle aspiration (EUS-FNA) or fine needle biopsy (EUS-FNB) is helpful for confirmation of tissue diagnosis and staging of tumor (eg, by obtaining the biopsy of metastatic liver lesions and lymph nodes). Identification of small pancreatic cancers is challenging in the presence of chronic pancreatitis where heterogeneous echogenicity of pancreatic tissue can mask hypoechoic malignant lesions which may result in

<table>
<thead>
<tr>
<th>Study</th>
<th>Year of study</th>
<th>Total no of patients</th>
<th>Sensitivity, EUS versus CT (%)</th>
<th>Specificity, EUS versus CT (%)</th>
<th>Accuracy, EUS versus CT (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Du et al</td>
<td>2017</td>
<td>68</td>
<td>98 vs 73*</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Kamata et al</td>
<td>2014</td>
<td>35</td>
<td>100 vs 56*</td>
<td>100 vs 100</td>
<td>NA</td>
</tr>
<tr>
<td>Kitano et al</td>
<td>2012</td>
<td>277</td>
<td>91 vs 71*</td>
<td>94 vs 92</td>
<td>NA</td>
</tr>
<tr>
<td>Sakamoto et al</td>
<td>2008</td>
<td>156</td>
<td>94 vs 50*</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Jemma et al</td>
<td>2008</td>
<td>42</td>
<td>100 vs 88*</td>
<td>89 vs 83</td>
<td>NA</td>
</tr>
<tr>
<td>Kitano et al</td>
<td>2004</td>
<td>65</td>
<td>95 vs 68*</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Agarwal et al</td>
<td>2004</td>
<td>81</td>
<td>100 vs 75*</td>
<td>NA</td>
<td>94 vs 74*</td>
</tr>
<tr>
<td>DeWitt et al</td>
<td>2004</td>
<td>120</td>
<td>98 vs 86*</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Rivadeneira et al</td>
<td>2003</td>
<td>48</td>
<td>100 vs 68*</td>
<td>75 vs 50*</td>
<td>98 vs 67*</td>
</tr>
<tr>
<td>Mertz et al</td>
<td>2000</td>
<td>35</td>
<td>93 vs 53*</td>
<td>NA</td>
<td>86 vs 49*</td>
</tr>
<tr>
<td>Gress et al</td>
<td>1999</td>
<td>151</td>
<td>100 vs 74</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Harrison et al</td>
<td>1999</td>
<td>19</td>
<td>100 vs 50*</td>
<td>NA</td>
<td>98 vs 63*</td>
</tr>
<tr>
<td>Midwinter et al</td>
<td>1999</td>
<td>48</td>
<td>97 vs 76</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Legmann et al</td>
<td>1998</td>
<td>30</td>
<td>100 vs 92</td>
<td>NA</td>
<td>93 vs 93</td>
</tr>
<tr>
<td>Sugiyama et al</td>
<td>1997</td>
<td>54</td>
<td>96 vs 89*</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Howard et al</td>
<td>1997</td>
<td>21</td>
<td>75 vs 63†</td>
<td>77 vs 100†</td>
<td>76 vs 86†</td>
</tr>
<tr>
<td>Meizer et al</td>
<td>1996</td>
<td>12</td>
<td>100 vs 83</td>
<td>NA</td>
<td>100 vs 76</td>
</tr>
<tr>
<td>Nakazumii et al</td>
<td>1995</td>
<td>232</td>
<td>94 vs 65*</td>
<td>97 vs 94</td>
<td>96 vs 88*</td>
</tr>
<tr>
<td>Marty et al</td>
<td>1995</td>
<td>37</td>
<td>92 vs 63</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Müller et al</td>
<td>1994</td>
<td>49</td>
<td>94 vs 69†</td>
<td>100 vs 64</td>
<td>96 vs 67</td>
</tr>
<tr>
<td>Palazzo et al</td>
<td>1993</td>
<td>64</td>
<td>96 vs 69†</td>
<td>73 vs 53</td>
<td>91 vs 66*</td>
</tr>
<tr>
<td>Yasuda et al</td>
<td>1993</td>
<td>29</td>
<td>100 vs 72†</td>
<td>NA</td>
<td>Duodenal Invasion: 83 vs 33</td>
</tr>
<tr>
<td>Rösch et al</td>
<td>1991</td>
<td>102</td>
<td>99 vs 77</td>
<td>100 vs 53</td>
<td>Gastric invasion: 79 vs 38</td>
</tr>
</tbody>
</table>

*Statistically significant data.
†Statistics are not available.
EUS, endoscopic ultrasound; NA, not applicable.
missed diagnosis. Patients with chronic pancreatitis are at increased risk of developing pancreatic cancer. EUS imaging finding supporting a diagnosis of pancreatic cancer in the setting of chronic pancreatitis are mass size above 2 cm, irregular dilation of the main pancreatic duct and branch duct, vascularity of mass, absence of cysts within mass and presence of lymphadenopathy and vascular invasion. To discriminate pancreatic cancers from inflammatory pancreatic masses, conventional EUS evaluation alone is often not enough despite high sensitivity and specificity over cross-sectional imaging. The introduction of contrast-enhanced (CE) EUS and EUS elastography may improve the evaluation of pancreatic cancers even in the presence of concomitant autoimmune pancreatitis (AIP) or chronic pancreatitis. CE-EUS is a technique which combines high-resolution endoscopy ultrasound waves with intravenous contrast. CE-EUS generates an acoustic signal when ultrasound waves interact with oscillating microbubbles in the intravenous contrast. These acoustic signals help in the assessment of vascularity of pancreatic masses in addition to providing information about echogenicity of lesions. CE-EUS features such as iso-enhancement or hypoenhancement, arterial irregularity and absent venous vasculature within a mass favours pancreatic ductal adenocarcinoma (PDAC) while hyperenhanced lesions with the preserved architecture of both arterial and venous microvasculature indicate chronic pancreatitis. CE-EUS can reliably differentiate pancreatic lesions from pancreatic cancer with sensitivity, specificity, positive predictive value and negative predictive value of 91%, 93%, 100% and 88% respectively. It also helps in differentiating pancreatic cystic lesions such as serous cystadenoma (enhancement of intracystic septation), mucinous cystic neoplasm (MCN) (irregular enhancement of intralossional septum and nodule), malignancy intraductal papillary mucinous neoplasms (IPMN) (invasive and papillary mural nodule) and benign IPMN (polyoidal non-invasive papillary nodule). A meta-analysis on 19 studies has shown pooled sensitivity 91%, specificity 86% for the diagnosis of focal pancreatic masses or PDAC.

Elastography is a newer non-invasive technique to evaluate stiffness (elasticity) of soft tissue. EUS transducer sends a shearing wave through the pancreas and generates an elastogram by calculating velocity faced by shearing wave while passing through soft tissue. EUS elastography works as an adjunct to EUS-FNA which may help in the differentiation of malignant from non-malignant masses. The diagnostic yield of EUS elastography in the differentiation of solid pancreatic cancers is variable, with three meta-analyses showing a 95%–97% pooled sensitivity and 67%–76% specificity.

An algorithm for the evaluation and management of patients with suspected pancreatic adenocarcinoma based on current guidelines is shown in figure 1. EUS-FNA should be performed whenever possible for resectable pancreatic cancers to rule out alternative diagnosis.

Figure 1  Algorithm for the evaluation and management of patients with suspected pancreatic adenocarcinoma (courtesy of American society of gastrointestinal endoscopy (ASGE) practice guidelines). EUS, endoscopic ultrasound; ERCP, endoscopic retrograde cholangiopancreatography; FNA, fine-needle aspiration.

It could be difficult to differentiate from pancreatic neoplasm and to confirm tissue diagnosis if needed in patients who are unresectable. In addition, having a tissue diagnosis of PDAC for resectable disease allows for possible neoadjuvant therapy options.

EUS evaluation of pancreatic cystic lesions

With the advancement of cross-sectional imaging, the detection rate of incidental pancreatic cyst has increased. The most common incidental pancreatic cystic lesions include mucinous cysts (eg, MCN and IPMNs) pseudo-cysts and serous cystadenomas. The mucinous cystic lesions (which are considered premalignant and occasionally malignant) need to be differentiated from non-mucinous lesions, as they appear with different prognoses and management. EUS and cross-sectional imaging both MRI/CT scans are generally considered to be complimentary for the evaluation of pancreatic cysts. Although MRI is considered superior in the evaluation of pancreatic cystic lesions, a distinct advantage of EUS (especially with improved image resolution) is the ability to sample pancreatic cyst fluid for both cytology and tumor markers including carcinoembryonic antigen (CEA) and DNA mutational analysis. Under current guidelines, EUS is increasingly reserved for pancreatic cysts with high-risk stigmata or worrisome features where it may impact on
Staging of pancreatic cancers

EUS is a useful modality for the staging of pancreatic cancers in patients with suspected malignancy and assisting in determining surgically resectable lesions. Due to their widespread availability and non-invasive nature, imaging with CT or MRI remains the first-line imaging of choice to perform staging of pancreatic malignancy. For example, advanced cross-sectional imaging from a multidetector CT allows the acquisition of pancreatic arterial phase, pancreatic parenchymal phase and portal venous phase imaging. Pancreatic parenchymal phase and portal venous phase are very useful tools in the identification and precise preoperative vascular staging of pancreatic cancers.61 However, EUS is still an effective tool for evaluation of vascular invasion of tumor, for example, portal vein, superior mesenteric artery (SMA) and superior mesenteric vein notably in patients with small size tumor and in those who cannot undergo CE CT or MRI due to other medical reasons.16 62 EUS also provides additional objective data on perivascular cuffing, assessment of liver masses and local lymph nodes for the staging of pancreatic cancers, especially in individuals who have undergone prior chemotherapy treatment.41 64

EUS-guided FNA

Indications

While CT and MRI imaging may identify a pancreatic mass and strongly suggest an underlying malignancy, pathological diagnosis is necessary to determine the benign or malignant nature of the mass. In the era prior to EUS, the tissue diagnosis of pancreatic masses used to be established by acquisition of tissue specimen by abdominal ultrasound, or CT-guided percutaneous biopsy, or ERCP-guided bile duct brush cytology, or on surgical exploration. The sensitivity of ERCP brush cytology is approximately 30% in the diagnosis of pancreatic malignancy.65 The utility of this approach is limited due to high rate of post ERCP pancreatitis and technical difficulty in obtaining cytology sample especially in case of benign stricture of the pancreatic duct.66 Currently, EUS-FNA biopsy is preferred over these other methods to obtain tissue and for establishing a diagnosis of pancreatic cancer. In case of pancreatic cystic lesions, EUS-FNA helps to distinguish pancreatic cysts with malignant potential (e.g., MCN and IPMN) from other cystic lesions without malignant potential (e.g., serous cystadenoma). Cyst fluid analysis for cytology, mucin containing goblet cells, tumor markers (CEA), DNA genetic mutation analysis (K-ras), and amylase may help to establish the diagnosis of pancreatic cystic lesions. Recent developments allow for the acquisition of cyst wall tissue by using a through-the-needle biopsy with moray forceps, in addition to the use of through-the-needle confocal microscope probes.

Technical feasibility considerations

EUS-FNA is the technique to obtain tissue for cytological evaluation which can be performed with a linear echoendoscope to target the pancreatic lesion under direct visualization. Tissue acquisition from uncinate, head and neck lesions can be performed by positioning endoscope in the duodenal bulb or second portion of duodenum while tissue from neck, body and tail lesions can be acquired by positioning endoscope in GOJ or proximal stomach. EUS-guided FNA needle targets the pancreatic lesion under direct visualization. Obtaining tissue sample from different areas of the pancreatic lesion is recommended by inserting the needle in a fanning fashion to maximise the yield of biopsy.66 67 Inserting FNA needle to target lesion closer to EUS probe is recommended for technical feasibility as the trajectory of needle may not be modified for distant lesions.68 69 Although there is a risk of needle tract seeding with EUS-FNA, this is often not a concern when the subsequent surgical management includes resection of the pancreatic head.70

Safety

EUS-FNA confers several advantages in the evaluation of pancreatic masses including the ability to target small lesions due to high-resolution imaging in close proximity to the pancreas, less risk to puncturing the intervening organs, avoidance of needle tract tumor seeding and overall cost-effectiveness particularly by avoiding unnecessary additional procedures. The rate of EUS-FNA-associated complications such as pancreatitis, infection, intestinal perforation, biliary peritonitis and malignant seeding is low as compared with other modalities.60 The overall complication rate of EUS-FNA is 2.5% which ensures diagnostic safety of this approach. The risk of pancreatitis ranges from 0.3% to 0.9% with EUS-FNA which is significantly lower than ERCP-guided brush cytology 0%–21.5% and percutaneous biopsies 4%.65 71 The risk of malignant peritoneal seeding is very low with EUS-FNA 2.2% as compared with percutaneous biopsy 16.3%.72

Accuracy

The diagnostic accuracy of EUS-FNA is high for establishing a diagnosis of pancreatic malignancy. EUS-FNA yields an accuracy of 85%–92%, sensitivity of 80%–95% and specificity of 92%–100% in diagnosing pancreatic malignancy.73 74 Several confounding factors such as tumor consistency, needle diameter, number of passes and availability of on-site cytopathologist can affect the diagnostic yield of EUS-FNA. Although the size of EUS-FNA needles varies from 19 to 25 gauge (G), however, most endosonographers use either 25 G or 22 G needles with the dedicated acquisition of tissue for making diagnosis of malignant lesions. A meta-analysis showed a higher yield for 25 G needles for diagnosis of pancreatic cancers with pooled sensitivity of 93% and specificity of 97% as compared with 22 G needle with 85% sensitivity and 99% specificity.75 While there is conflicting information about
the yield of needle size, the added advantage of smaller gauge needles exhibit less risk of bleeding and easy penetration through desmoplastic tissues. The utilization of rapid on-site evaluation (ROSE) of cytology specimens has significantly reduced the need for multiple needle passes for making a diagnosis whereby the presence of an on-site cytopathologist advises about specimen adequacy and real-time diagnosis during the procedure. Multiple studies have shown an increase in the diagnostic yield of this approach by 10%-30% with an accuracy of 93.3%-96.8%, sensitivity of 88.6%-96.2% and specificity of 99%-100%.78–81

**Endoscopic ultrasound fine needle biopsy**

**Indications**

Differentiating pancreatic malignancy from AIP, chronic pancreatitis and pancreatic lymphoma or tuberculosis may be challenging because EUS-FNA may not provide sufficient tissue for molecular and histological evaluation of malignancy.82 EUS-FNB provides core tissue with preserved architecture of desmoplastic stroma and glandular tissues to establish histological diagnosis of PDAC and to differentiate malignancy from AIP, chronic pancreatitis, pancreatic lymphoma or tuberculosis. In addition, it may provide additional tissue for molecular profiling (such as immunohistochemistry, DNA sequencing or RNA-based marker studies) and when morphological retention of tissue architecture is needed for establishing diagnosis and management.

**Technical feasibility considerations**

EUS-FNB is a technique similar to EUS-FNA to acquire tissue for histological evaluation. There are various types of FNB needles including a Fork tip, a Franseen tip and a side opening needle which are designed to obtain a core sample from the target tissue. The Fork tip needle design has an additional sharp tip while the Franseen needle has three cutting edges. A recent randomised control trial (RCT) and a meta-analysis on 21 studies showed no significant difference in diagnostic yield of Franseen tip needle 92.7%-94% as compared with Fork tip FNB needle 98%.83 84 Only one RCT showed higher diagnostic yield of 19G FNB needle 89.5%, compared with 22G needle 82.5% and 25 G needle 63%.85 The selection of FNB needle is based on cost of needle and physicians preference without compromising diagnostic accuracy of procedure.

**Safety**

The safety profile EUS-FNB is comparable with EUS-FNA. EUS-FNB appears to be a cost-effective approach, which provides adequate tissue sample with fewer needle passes to establish diagnosis.86 87 Whereas initially EUS-FNB was being used as salvage procedure in case of unsatisfactory FNA sampling for making diagnosis, more recently FNB is replacing FNA for tissue acquisition and may completely eradicate the need for ROSE.87 A meta-analysis has shown pooled diagnostic yield of FNB without and with ROSE and found no difference between two approaches 95.9% vs 93.7%, respectively.84 This approach may ultimately cut down the procedural time, hospital cost and minimise resource utilization.

**Accuracy**

The accuracy of EUS-FNB is promising in the diagnosis of pancreatic malignancy when higher tissue cellularity and core histological sample is required. A recent study showed 90% accuracy of FNB using the Franseen biopsy needle.86 It provides a dedicated tissue sample for molecular profiling and preserves structural integrity for histological analysis. A multicentre RCT showed 91.4% accuracy of FNB samples as compared with FNA sample 80% for the diagnosis of pancreatic masses, while no difference was found in the diagnostic yield of non-pancreatic masses.89 Another meta-analysis on 11 studies has shown higher accuracy of FNB (OR: 1.62) for diagnosis of solid pancreatic cancers as opposed to FNA.84 There was no difference in rate of complications and technical success between two approaches. Several RCTs have shown the superiority of FNB over FNA to diagnose pancreatic cancers while some RCT showed no difference in diagnostic accuracy, sensitivity and specificity between two techniques (table 2).89–94

<table>
<thead>
<tr>
<th>Study</th>
<th>Year of study</th>
<th>Total no of patients</th>
<th>Accuracy/diagnostic yield, FNA versus FNB (%)</th>
<th>Sensitivity, FNA versus FNB (%)</th>
<th>Specificity, FNA versus FNB (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cheng et al80</td>
<td>2018</td>
<td>408</td>
<td>80 vs 91.4*</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Van Riet et al82</td>
<td>2019</td>
<td>608</td>
<td>87 vs 78*</td>
<td>90 vs 82*</td>
<td>96 vs 91</td>
</tr>
<tr>
<td>Wang et al83</td>
<td>2016</td>
<td>408</td>
<td>80 vs 93</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Vanbiervliet et al81</td>
<td>2014</td>
<td>80</td>
<td>92.5 vs 90</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Lee et al84</td>
<td>2014</td>
<td>118</td>
<td>94.8 vs 98.3</td>
<td>94.6 vs 98.2</td>
<td>100 vs 100</td>
</tr>
<tr>
<td>Strand et al85</td>
<td>2014</td>
<td>32</td>
<td>93.8 vs 28.1*</td>
<td>NA</td>
<td>NA</td>
</tr>
</tbody>
</table>

*Statistically significant data.

EUS, endoscopic ultrasound; FNA, fine-needle aspiration; FNB, fine-needle biopsy; NA, not applicable; RCT, randomised control trial.
**EUS-GUIDED THERAPEUTIC INTERVENTIONS**

**Endoscopic ultrasound-guided biliary drainage**

**Indications**

In current practice, the most commonly used method for biliary drainage (BD) in the setting of pancreatic malignancy is ERCP-guided drainage which typically shows an excellent success rate of over 90%. BD with ERCP is challenging in cases of benign or malignant stricture of oesophagus or duodenum, anatomic or pathological abnormality of ampulla (such as malignant infiltration of ampulla or periampullary diverticulum), and in case of altered anatomy of gastrointestinal tract after bariatric gastric bypass surgeries. Due to difficult access to the ampulla, percutaneous transhepatic BD (PTBD) or surgical decompression are alternative procedures of choice after failed ERCP. The associated morbidities (such as risk of bleeding, infections, cholangitis, pancreatitis, catheter dislocation and bile leak) are high with these procedures (up to 33%). The failure rate of ERCP BD is 3%–10% specifically due to ampullary infiltration of pancreatic cancers. Currently, there is increasing use of EUS-BD in these patients.

**Technical feasibility considerations**

EUS-BD can be performed with either intraduodenal or extraduodenal techniques depending on the patient’s anatomy and technical feasibility. The intraduodenal techniques are EUS-guided hepaticogastrostomy with antegrade stent placement where the tip of EUS scope is positioned along the lesser curvature of the stomach to visualize diluted left hepatic duct. Under EUS and fluoroscopic guidance, a 19–22 G transgastric needles inserted into the lumen of the left hepatic duct. The needle track is dilated over the guidewire with a 6.5 Fr cystotome to create a hepato gastric fistula and a fully covered self-expanding metal stent or lumen apposing metal stent (LAMS) can be placed for biliary decompression. A transpapillary stent could be deployed with antegrade advancement of the wire or with an EUS-guided rendezvous (EUS-RV) technique. In EUS-RV, a dilated biliary duct is punctured with a 19G needle, the guidewire is advanced through needle into duodenal lumen in an antegrade fashion and finally, retrograde cannulation of common bile duct (CBD) is performed with ERCP duodenoscopy using the EUS directed guidewire.

The extraduodenal techniques include EUS-guided cholecdochojunostomy where the dilated CBD can be visualized by positioning tip of EUS scope in the duodenal bulb or antrum. After inserting a 19 G transduodenal needle into CBD, needle track is created over 0.035-inch guidewire and transluminal or transpapillary stent is deployed. Metal stent are preferred over plastic stents due to better safety profile, less risk of stent-related complications.

**Safety**

EUS-BD is an emerging technique with both technical and functional success rate over 90%. The technical and clinical success rates of EUS-BD and ERCP-BD are comparable, however, the advantages of EUS-BD over ERCP-BD are lower adverse outcomes with low risk of postprocedure pancreatitis, longer stent patency with decreased re-intervention need and increased quality of life. After failed ERCP, EUS-BD is a promising salvage technique due to high technical feasibility and low risk of complications compared with PTBD and surgical biliary decompression. The overall reported risk of complications due to EUS-BD is 5%–10%. A meta-analysis on 42 studies showed complications associated with EUS-BD are bile leakage 4.03%, haemorrhage 4.03%, perforation 3.02%, migration of stent 2.68%, infections 1.26%–2.43% and postprocedure pain 1.51%. The utility of metal stents has significantly reduced stent-related complications of BD. When comparing intraduodenal with extraduodenal biliary decompression, there is no difference in success rate (90.4% vs 84.3%) and overall outcome (32.6% vs 35.6%) between two approaches.

**Accuracy**

The efficacy and technical success rate of EUS-BD is improving. The rate of complications can be reduced by performing this procedure in expert centres. The long learning curve of this technique is directly associated with low rates of complications and high success rate. A group of 40 international experts suggested that EUS-BD should be performed by an expert endoscopist who master the EUS and ERCP techniques and has at least 4–5 years of experience (approximately 200–300 EUS and ERCP annually) with success rate over 95% for standard ERCP. Currently, there are no significant data on the accuracy of EUS-BD due to limited use of this technique as ERCP-BD is still the first-line procedure of choice for biliary decompression whenever possible. Further RCTs are required to determine further safety and accuracy of EUS-BD. The selection of intraduodenal or extraduodenal techniques is based on the patient’s clinical presentation, anatomical location of pathologic lesions and preference of endoscopist.

**Endoscopic ultrasound-fine needle injection**

**Indications**

EUS-fine needle injection (FNI) is a rapidly emerging technique to deliver implants and injections into pancreatic lesions under direct EUS visualization. The precarrier EUS-guided injection of dyes to tattoo tumor is increasingly used for localization of operable pancreatic lesions. EUS-guided implantation of fiducial markers into the tumor enables targeted radiation therapy to the pancreatic tumors. Similarly, the direct injection of certain antitumor agents into the tumor may provide localized chemotherapy. The advantage of localized chemotherapy is to expose targeted lesion with high concentration of chemotherapeutic agents while minimizing the risk of systemic toxicities.
Technical feasibility considerations
A 19G or 22G fine needle is inserted into the targeted lesions under direct EUS visualization. EUS-guided fine needle tattooing (EUS-FNT) is usually performed by injecting 2–5 mL sterile dye (carbon particles, indocyanine or India ink) into normal pancreatic tissue 2 cm away from tumor margins. A number of EUS-FNI agents, including ethanol, antitumor adenovirus vector (ONYX-015, TNERade.), antitumor therapy (dendritic cells), gemcitabine, paclitaxel, have been experimentally used in humans with similar techniques. Additionally, EUS-guided placement of fiducial markers directly into pancreatic tumors, may be useful in radiation treatment planning.

Safety and accuracy
EUS-FNI is a very safe and minimally invasive method for both therapeutic and diagnostic interventions in the management of pancreatic cancers. The advantage of preoperative EUS-FNT is accurate identification of small pancreatic tumors during surgical resection which results in limited resection of pancreatic tissue, shorter operative time and fewer surgical complications. The technical success rate of EUS-brachytherapy (placement of radioactive seeds directly into the pancreas) is 85%–100%. EUS-guided brachytherapy, have shown an improvement in pain symptoms but not overall survival.

EUS-guided celiac plexus neurolysis and celiac plexus block
The injection of nerve-blocking agents using the celiac plexus neurolysis (CPN) plays an important role in the management of palliative pain in unresectable pancreatic cancers.

Indications
Pain management in pancreatic cancers is sometimes challenging in cases of inadequate pain control with non-narcotic medications and contraindications to opioid therapy. EUS-guided CPN is a well-accepted nonpharmacological treatment option for pain management to improve quality of life. In patients with unresectable pancreatic cancers, EUS-CPN is associated with better pain control and reduction in the consumption of opioids.

Technical feasibility considerations
The celiac plexus is located below the diaphragm adjacent to the anterolateral aspect of the celiac trunk. EUS identifies the location of the celiac plexus at the junction between the celiac trunk and aorta. There are two types of endoscopic approaches for performing CPN including ‘central’ and ‘bilateral’ techniques. A linear echoendoscope is positioned in the body of the stomach to identify abdominal aorta. The echoendoscope traces the aorta down to the celiac trunk. In the central approach, the needle is directed centrally at the junction of aorta and the celiac artery. In the bilateral approach, the echoendoscope is rotated clockwise to advance the needle adjacent to the celiac artery to the point of origin of SMA from aorta. A 10 mL of 0.25% bupivacaine is injected adjacent and anterior to the celiac artery depending on above-mentioned approaches. This is followed by the injection of neurolytic agents either 10 mL of dehydrated 98% alcohol or phenol. A dedicated 20 G needle with multiple side holes assists in the effective spread of injecting agents into the celiac plexus is available. The needle should be flushed with 3 mL of normal saline before withdrawal to prevent postprocedural abdominal pain secondary to the seeding of neurolytic agent in the needle track.

Safety and accuracy
EUS-guided CPN is a relatively safe alternative than CT or fluoroscopically guided plexus neurolysis in the management of pancreatic cancer pain. A meta-analysis on pain management in pancreatic cancer patients showed a long-term success rate of 72% with EUS-CPN and is a reasonable option for patients with tolerance to narcotic analgesics. Another meta-analyses including 17 studies have shown 80.12% pooled pain relief related to pancreatic cancers with EUS-CPN techniques. The pain-relieving effect of the bilateral technique is long-lasting and much higher 84.54% than central technique 45.99%. Overall EUS-CPN and EUS-ceeliac plexus block (CPB) are safe, and effective palliative methods in pancreatic cancers which allow the patients to cut-down their narcotics and improve their pain control. Moreover, the injection on both sides of the celiac artery had a higher pain-relieving success rate compared with injection on one side (85% vs 46%). The reported rate of complications is 2%-7% with EUS-CPB while up to 21% with EUS-CPN which is relatively lower than other modalities. The most common transient complications are local pain (36%), hypotension (33%) and diarrhea (23%).

Role of EUS in gastric outlet obstruction
Indications
Pancreatic cancers are associated with gastric outlet obstruction (GOO) in approximately 10%–20% patients. The progression of primary pancreatic tumor causes GOO due to extrinsic duodenal compression in most cases. Nausea, nonbilious vomiting, symptoms of malnutrition and dehydration are the initial symptoms of GOO. The quality of life in these patients is poor due to malnourishment and pancreatic cancer pain. The goal of palliative treatment is to relieve symptoms of GOO and improve nutritional status. Typically, palliative treatment of malignant GOO has been performed with established methods including open or laparoscopic surgical gastrojejunostomy (GJ) and duodenal stenting. Recently established minimal invasive endoscopic techniques including EUS-GJ are novel and promising modalities in the management of GOO.

Technical feasibility considerations
EUS-GJ is technically challenging than conventional duodenal stenting and should be performed by the expert therapeutic endoscopist. In the direct
EUS-gastroenterostomy (GE) approach, a therapeutic forward-viewing echoendoscope is used to fill small bowel with mixture of saline, contrast and methylene blue. A transgastric 19 G needle is used to puncture small bowel distal to GOO. The needle position is confirmed with the aspiration of blue-tinged fluid and enterogram. After withdrawing the needle, a cautery assisted LAMS is deployed across small bowel and gastric body. A balloon-assisted GE is another approach of EUS-GJ in which a guide-wire is placed across the GOO, followed by inflation of the balloon with contrast fluid. The contrast filled balloon is then punctured with EUS-guided 19 G needle transgastrically. A guidewire is then advanced into small bowel followed by deployment of LAMS to create gastroenterostomy.

Safety and accuracy
EUS-GJ is a safe modality in the management of malignant GGO. These minimally invasive techniques offer the potential benefits of surgical bypass with higher technical success (90%-100%), clinical success rates (80%-95%) and low risk of adverse events or procedural complications. The reported complications of EUS-GJ are perforation, peritonitis, haemorrhage and luminal obstruction of the stent due to food impaction. EUS-GE should be avoided in patients with perigastric varices and those with massive ascites due to increased intra-abdominal pressure. Patients showed recurrent symptoms requiring reintervention.124–128

Conclusion
EUS plays an important role in the evaluation of pancreatic masses and in determination of the accurate stage of pancreatic cancers by providing cytological and histological confirmation. Additionally, EUS-GJ of pancreatic cancers by providing cytological and histological masses and in determination of the accurate stage of pancreatic cancers by providing cytological and histological confirmation. Additionally, EUS-GJ is an important tool for diagnostic and therapeutic interventions are promising modalities providing technical success (90%–100%), clinical success rates (80%–95%) and low risk of adverse events or procedural complications.124–128


REFERENCES


70 van Heerde MJ, Biermann K, Zondervan PE, et al. Prevalence of autoimmune pancreatitis and other benign disorders in...


